drugset / Trial / NCT01813318

Study of Acamprosate in Autism

NCT01813318

RandomizedParallel-groupQuadruple-blindBasic science

Summary

Recent pharmacotherapy research in autism spectrum disorders (ASD) has successfully focused on treatment of co-occurring symptoms, including inattention, hyperactivity, and irritability that commonly occur in persons with ASD. Despite over two decades of significant pharmacotherapy research, to date no medication has been shown in controlled trials to enhance the core social deficits of ASD. Based upon findings describing the neurobiology of ASD combined with our preliminary results, we believe the novel drug acamprosate will show evidence of reducing social skills deficits associated with ASD.

Timeline

Start
2013-07-02
Primary completion
2017-09-07
Completion
2017-09-07

Drugs

EvaluationDrugModalityDoseRoute
Comparator Acamprosate Small molecule 1332 mg
Comparator Acamprosate Small molecule 1998 mg

Indications